ArticleGenome medicine2022
Intratumor heterogeneity and T cell exhaustion in primary CNS lymphoma.
Article in Genome medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Unveiling the role of spatial transcriptomics in the analysis of the tumor immune microenvironment (Review).International journal of molecular medicine · 2026Review
- Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics.Biomarker research · 2026Review
- Genetic orchestration of the primary central nervous system lymphoma microenvironment.Biomarker research · 2026Review
- A Tumor-Boundary Niche Enriched for PD-1Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in deciphering intratumoral versus peritumoral heterogeneity of infiltrating lymphocytes in pancreatic cancer: a spatial perspective.Translational oncology · 2026Review
- Spatial and multi-omic profiling reveals pericyte-derived CCL19 as a key prognostic factor in CNS lymphoma.HemaSphere · 2026Article
- Unraveling the immune microenvironment in primary CNS lymphoma.Biomarker research · 2026Review
- C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions.Cancer pathogenesis and therapy · 2026Review
- CoMBCR: Co-Learning Multi-Modalities of BCRs and gene expressions.Bioinformatics (Oxford, England) · 2026Article
- Construction and validation of nomogram for the cancer-specific death in children and adolescents‑onset lymphoma.Discover oncology · 2026Article
- Dual-mode microfluidic immunostaining device for diagnostic biomarkers detection and tumor microenvironment evaluation.Science advances · 2026Article
- The impact of the large B-cell lymphoma tumor microenvironment on efficacy of CD19-directed CAR-T immunotherapy.Frontiers in immunology · 2026Review
- Durable Complete Remission Achieved by Tirabrutinib Rechallenge in Relapsed Primary Central Nervous System Lymphoma: A Case Report.NMC case report journal · 2026Article
- Advancements in Nanomedicine for Precision Management of Lymphoma: Mechanisms, Diagnostics, and Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Prediction of double expression status of primary CNS lymphoma using multiparametric MRI radiomics combined with habitat radiomics: a double-center study.Journal of neuro-oncology · 2025Article
- Plasmablast-like lymphoma cells as a distinct subpopulation confer multidrug resistance in PCNSL.Neuro-oncology · 2025Article
- Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM.Cancer discovery · 2025Article
- Integrating bulk and single-cell RNA sequencing reveals intratumor heterogeneity phenotypes and immune infiltration in pancreatic cancer.Discover oncology · 2025Article
- Paradigms, innovations, and biological applications of RNA velocity: a comprehensive review.Briefings in bioinformatics · 2025Review
- Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma.Blood neoplasia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary central nervous system lymphoma (PCNSL) is a rare lymphoma of the central nervous system, usually of diffuse large B cell phenotype. Stereotactic biopsy followed by histopathology is the diagnostic standard. However, limited material is available from CNS biopsies, thus impeding an in-depth characterization of PCNSL.
methodsWe performed flow cytometry, single-cell RNA sequencing, and B cell receptor sequencing of PCNSL cells released from biopsy material, blood, and cerebrospinal fluid (CSF), and spatial transcriptomics of biopsy samples.
resultsPCNSL-released cells were predominantly activated CD19
conclusionsMalignant B cells in PCNSL show transcriptional and spatial intratumor heterogeneity. T cell exhaustion is frequent in the PCNSL microenvironment, co-localizes with malignant cells, and highlights the potential of personalized treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.